Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28269131 | 0.99 | AAK1 (0.51) | AAK1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL28269146 | 0.96 | AAK1 (0.53) | AAK1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL8199100 | 0.88 | AAK1 (0.50) | AAK1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL28269214 | 0.86 | AAK1 (0.65) | AAK1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL28269144 | 0.86 | AAK1 (0.67) | AAK1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL14493754 | 0.85 | AAK1 (0.54) | AAK1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL18762512 | 0.85 | AAK1 (0.73) | AAK1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL18762542 | 0.85 | AAK1 (0.73) | AAK1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL18762511 | 0.85 | AAK1 (0.73) | AAK1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL28367638 | 0.83 | AAK1 (0.46) | AAK1MEN1KMT2ATDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164186-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164186-A1 | BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| CN-109280075-B | Peptide amide compound, preparation method and medical application thereof | 四川海思科制药有限公司 | 2022-05-20 | — | — | CN | disclosed |
| CN-109280075-A | Peptide amide class compound and preparation method thereof and purposes in medicine | 四川海思科制药有限公司 | 2019-01-29 | — | — | CN | disclosed |
| US-8513253-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1465861-B1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1465861-A4 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1465861-A1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | disclosed |
| WO-2003053912-A1 | α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | AAK1 164/4885MEN1 3211/4885KMT2A 3511/4885 |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | APP, APBA1, BACE1 | AAK1 164/4885MEN1 3211/4885KMT2A 3511/4885 |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | APBA1, APP, BACE1 | AAK1 191/4885MEN1 2552/4885KMT2A 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.